Lexington BioSciences Inc (CSE: LNB), aims to become a leader in the development of clinical grade cardiovascular self-measurement solutions for home and clinical use.
Lexington is currently taking steps to commercialize a universal, simple, effective and revolutionary technology for personalized measurement and monitoring of vascular health to prevent cardiovascular disease at its earliest stages.
The device, brand named HEARTSENTRY, has been extensively tested to measure the function of the endothelium, the cells that line all arteries and are critical to the prevention of atherosclerosis, heart attacks and stroke, the two leading causes of death world-wide with over 17.5 million deaths each year. *
The significant value of measuring endothelial function is supported by thousands of peer-reviewed studies. For ease of use and familiarity, this life saving technology has been combined into traditional blood pressure cuff equipment.
The unit is designed to utilize Bluetooth and Cloud technology to provide up-to-date and accurate readings of an individual’s complete cardiovascular health via electronic monitoring for risk-assessment and treatment effectiveness targeting the prevention of heart attack and stroke.
Our top scientific research support and prudent business leadership aims to realize the successful introduction of this potentially disruptive technology to directly target the unmet medical need for early detection in this rapidly growing global marketplace.